Use este identificador para citar ou linkar para este item: https://repositorio.inpa.gov.br/handle/1/36637
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorMelo Silva, Jean de-
dc.contributor.authorPinheiro-Silva, Renato-
dc.contributor.authorDhyani, Anamika-
dc.contributor.authorPontes, Gemilson Soares-
dc.date.accessioned2020-11-18T20:18:12Z-
dc.date.available2020-11-18T20:18:12Z-
dc.date.issued2020-
dc.identifier.urihttps://repositorio.inpa.gov.br/handle/1/36637-
dc.description.abstractCytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections are widely distributed throughout the world. EBV is linked to various hematological and autoimmune disorders whereas CMV might play important role in the progression of chronic hematological diseases, such as hemoglobinopathies, lymphomas, myelomas, hemophilia, and aplastic and sickle cell anemia. Both viruses produce a viral homolog of human interleukin-10 that can cause general suppression of immune response, increasing susceptibility to other infections. These viruses can remain latent in the host cells and be reactivated when the host immune system is compromised. Studies showing the impact of CMV and EBV infections on hematological disorders are scarce and unclear in the context of coinfection. This review intends to present the biology, prevalence, and impact of CMV and EBV infections in patients with hematological diseases. Copyright © 2020 Jean de Melo Silva et al.en
dc.relation.ispartofVolume 2020, Númeropt_BR
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Brazil*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/br/*
dc.titleCytomegalovirus and Epstein-Barr Infections: Prevalence and Impact on Patients with Hematological Diseasesen
dc.typeArtigopt_BR
dc.identifier.doi10.1155/2020/1627824-
dc.publisher.journalBioMed Research Internationalpt_BR
Aparece nas coleções:Artigos

Arquivos associados a este item:
Arquivo TamanhoFormato 
artigo-inpa.pdf1,14 MBAdobe PDFVisualizar/Abrir


Este item está licenciada sob uma Licença Creative Commons Creative Commons